Ascendis Pharma A/S (ASND) Earnings Date & Reports

Key Takeaways

• Analysts expect first quarter 2026 revenue of approximately €270 million, representing over 160% year-over-year growth from €101 million in Q1 2025.
• Consensus EPS estimate stands at -€0.15, an improvement from the -€1.58 reported in the prior-year quarter.
• YORVIPATH, the company's lead product for hypoparathyroidism, is projected to drive the bulk of growth following €477 million in full-year 2025 sales.
• SKYTROFA sales expected to contribute steadily, with recent FDA approval for adult growth hormone deficiency expanding the market.
• Strong cash position of €616 million at year-end 2025 supports ongoing pipeline development.
• Investors watching for updates on TransCon CNP PDUFA outcome and 2026 cash flow guidance reaffirmation.

Earnings Context and Why It Matters

Ascendis Pharma A/S, a biopharmaceutical company focused on rare endocrine diseases using its TransCon prodrug technology, has seen explosive growth from commercial launches of YORVIPATH and SKYTROFA. Full-year 2025 revenue reached €720 million, up nearly 100% year-over-year, driven by YORVIPATH's rapid U.S. adoption with over 5,300 patient enrollments. This upcoming first quarter earnings report, set for May 7, 2026, will provide the first glimpse into 2026 performance amid international expansions and pipeline milestones. For investors, it offers critical insights into sustained demand, margin improvements, and progress toward the company's €5 billion revenue aspiration by 2030, influencing valuation in a competitive biotech sector.

Earnings Expectations

Wall Street anticipates robust top-line growth for the first quarter ended March 31, 2026. Consensus revenue estimates average €269.64 million across 11 analysts, a 167% increase from €101 million in Q1 2025, fueled by YORVIPATH's U.S. momentum and SKYTROFA's steady contributions. EPS consensus is -€0.15 (normalized) from two analysts, reflecting ongoing R&D investments but improved from last year's deeper loss.

Key metrics to watch include YORVIPATH net product sales, patient starts, prescriber growth, and international reimbursement progress, now available in over 30 countries. Company guidance from Q4 calls for €500 million in 2026 operating cash flow, which management may refine. Historically, Ascendis has beaten revenue expectations in recent quarters, with shares rising post strong Q4 2025 results on €248 million total revenue.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

Heading into earnings, sentiment is optimistic, with shares trading near 52-week highs around $229 after a strong Q4 2025 beat. Analysts maintain bullish ratings, citing commercial traction and pipeline potential. Risks include reimbursement hurdles internationally and R&D spend pressures. Past earnings have elicited positive moves on revenue beats, but misses on guidance could pressure the stock amid high growth expectations.

Forward Outlook and Key Factors to Monitor

Following Q1 results, investors should track confirmation of full-year 2026 cash flow guidance at €500 million, signaling operational leverage from scaling sales. YORVIPATH's global rollout, targeting full commercial launches in 10 more countries by year-end, will be pivotal for sustained growth.

Pipeline catalysts loom large: updates on TransCon CNP (navepegritide) for achondroplasia post its February 28 PDUFA date, including any FDA feedback or label expansions. Phase 3 initiations for SKYTROFA in new indications like idiopathic short stature and the Phase 2 COACH trial Week 78 data expected Q2 2026 could expand addressable markets.

Balance sheet strength with €616 million cash supports R&D, while monitoring gross margins amid manufacturing ramp-up and cost trends will gauge profitability path. Broader biotech sector dynamics, including M&A (mergers and acquisitions) interest in rare disease players, may also influence sentiment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations